Cargando…

Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?

The immune checkpoint inhibitors have significantly modified the therapeutic landscape of advanced non-small cell lung cancer in second-line and, more recently, first-line settings. Because of the superior outcome with pembrolizumab as an upfront strategy, PD-L1 status should now be considered a new...

Descripción completa

Detalles Bibliográficos
Autores principales: Remon, Jordi, Besse, Benjamin, Soria, Jean-Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346853/
https://www.ncbi.nlm.nih.gov/pubmed/28285592
http://dx.doi.org/10.1186/s12916-017-0819-3